AI Article Synopsis

  • Menopause is linked to high cholesterol levels and a greater risk of heart-related diseases, traditionally thought to be caused by low estrogen levels.
  • Research shows a positive correlation between elevated follicle-stimulating hormone (FSH) and increased cholesterol, even when estrogen levels are considered.
  • Blocking FSH signaling in experiments on mice helps lower cholesterol levels, suggesting that targeting FSH could be a new treatment option for managing high cholesterol in menopausal women, especially those in the peri-menopausal stage.

Article Abstract

Menopause is associated with dyslipidemia and an increased risk of cardio-cerebrovascular disease. The classic view assumes that the underlying mechanism of dyslipidemia is attributed to an insufficiency of estrogen. In addition to a decrease in estrogen, circulating follicle-stimulating hormone (FSH) levels become elevated at menopause. In this study, we find that blocking FSH reduces serum cholesterol via inhibiting hepatic cholesterol biosynthesis. First, epidemiological results show that the serum FSH levels are positively correlated with the serum total cholesterol levels, even after adjustment by considering the effects of serum estrogen. In addition, the prevalence of hypercholesterolemia is significantly higher in peri-menopausal women than that in pre-menopausal women. Furthermore, we generated a mouse model of FSH elevation by intraperitoneally injecting exogenous FSH into ovariectomized (OVX) mice, in which a normal level of estrogen (E2) was maintained by exogenous supplementation. Consistently, the results indicate that FSH, independent of estrogen, increases the serum cholesterol level in this mouse model. Moreover, blocking FSH signaling by anti-FSHβ antibody or ablating the FSH receptor (FSHR) gene could effectively prevent hypercholesterolemia induced by FSH injection or high-cholesterol diet feeding. Mechanistically, FSH, via binding to hepatic FSHRs, activates the Gi2α/β-arrestin-2/Akt pathway and subsequently inhibits the binding of FoxO1 with the SREBP-2 promoter, thus preventing FoxO1 from repressing SREBP-2 gene transcription. This effect, in turn, results in the upregulation of SREBP-2, which drives HMGCR nascent transcription and de novo cholesterol biosynthesis, leading to the increase of cholesterol accumulation. This study uncovers that blocking FSH signaling might be a new strategy for treating hypercholesterolemia during menopause, particularly for women in peri-menopause characterized by FSH elevation only.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355920PMC
http://dx.doi.org/10.1038/s41422-018-0123-6DOI Listing

Publication Analysis

Top Keywords

blocking fsh
16
cholesterol biosynthesis
12
serum cholesterol
12
fsh
12
cholesterol
8
hepatic cholesterol
8
reduces serum
8
estrogen addition
8
fsh levels
8
mouse model
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!